Genenta Shareholders Greenlight €300M Capital Raise and Reverse Stock Split

summarizeSummary

Genenta Science shareholders approved a €300 million capital raise authorization and a reverse stock split, giving the board authority to issue up to 120 million new shares—a potential dilution far exceeding the company's current market cap.

check_boxKey Events · Financing and Capital Events · GNTA

• €300M Capital Raise Approved

  Shareholders authorized the board to increase share capital by up to €300 million, including share premium, and issue up to 120 million new ordinary shares over five years. At the current market cap of ~$35 million, this represents potential dilution of over 300% if fully executed.

• Reverse Stock Split Authorized

  A reverse stock split at a ratio between 1:10 and 1:20 was approved, with the board authorized to implement it within 12 months. The split is intended to help maintain Nasdaq's minimum bid price compliance, a critical listing requirement.

• Name Change Deferred

  The proposal to rename the company to Saentra Forge S.p.A. was deferred to a reconvened meeting on September 10-11, 2026, to allow further evaluation of branding and corporate identity strategy.

• Board Gains Sweeping Discretion

  The board now has authority to determine the terms, timing, and structure of future issuances, including for strategic transactions, capital raises, and equity incentive plans, without further shareholder approval.

auto_awesomeAnalysis · GNTA · Life Sciences

Shareholders have handed Genenta Science's board sweeping authority to raise up to €300 million and execute a reverse stock split at a ratio between 1:10 and 1:20. The capital authorization allows the issuance of as many as 120 million new shares—a potential dilution that dwarfs the company's current $35 million market cap. The reverse split is explicitly aimed at maintaining Nasdaq's minimum bid price, a critical compliance issue. While the corporate name change to Saentra Forge was deferred to September, the capital and reverse split approvals are the main event. Against the backdrop of an activist shareholder group holding 23% and recent court battles over voting rights, this vote signals that management now has the tools to execute a dramatic restructuring—but existing shareholders face extreme dilution risk.